339 related articles for article (PubMed ID: 15647251)
1. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
2. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
3. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
4. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
[TBL] [Abstract][Full Text] [Related]
5. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
6. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.
Elli S; Guerrini M
Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
8. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
Casu B; Guerrini M; Naggi A; Perez M; Torri G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
Biochemistry; 2002 Aug; 41(33):10519-28. PubMed ID: 12173939
[TBL] [Abstract][Full Text] [Related]
9. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides.
Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097
[TBL] [Abstract][Full Text] [Related]
10. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
11. Non-anticoagulant heparins and inhibition of cancer.
Casu B; Vlodavsky I; Sanderson RD
Pathophysiol Haemost Thromb; 2008; 36(3-4):195-203. PubMed ID: 19176992
[TBL] [Abstract][Full Text] [Related]
12. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
Irimura T; Nakajima M; Nicolson GL
Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
[TBL] [Abstract][Full Text] [Related]
13. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
[TBL] [Abstract][Full Text] [Related]
15. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.
Casu B; Naggi A; Torri G
Matrix Biol; 2010 Jul; 29(6):442-52. PubMed ID: 20416374
[TBL] [Abstract][Full Text] [Related]
16. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
Bisio A; Mantegazza A; Urso E; Naggi A; Torri G; Viskov C; Casu B
Semin Thromb Hemost; 2007 Jul; 33(5):488-95. PubMed ID: 17629845
[TBL] [Abstract][Full Text] [Related]
17. Production of heparin and λ-carrageenan anti-heparanase derivatives using a combination of physicochemical depolymerization and glycol splitting.
Poupard N; Groult H; Bodin J; Bridiau N; Bordenave-Juchereau S; Sannier F; Piot JM; Fruitier-Arnaudin I; Maugard T
Carbohydr Polym; 2017 Jun; 166():156-165. PubMed ID: 28385219
[TBL] [Abstract][Full Text] [Related]
18. Turnover of heparan sulfate depends on 2-O-sulfation of uronic acids.
Bai X; Bame KJ; Habuchi H; Kimata K; Esko JD
J Biol Chem; 1997 Sep; 272(37):23172-9. PubMed ID: 9287321
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity of heparanases from human hepatoma and platelets.
Pikas DS; Li JP; Vlodavsky I; Lindahl U
J Biol Chem; 1998 Jul; 273(30):18770-7. PubMed ID: 9668050
[TBL] [Abstract][Full Text] [Related]
20. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
